Literature DB >> 4020142

Immune responses during human Schistosomiasis mansoni. XI. Immunologic status of patients with acute infections and after treatment.

G Gazzinelli, J R Lambertucci, N Katz, R S Rocha, M S Lima, D G Colley.   

Abstract

Sixteen patients, 8 to 30 yr of age, with acute (toxemic) phase schistosomiasis mansoni were studied immunologically within 2 to 3 mo of their exposure to Schistosoma mansoni cercariae, and were monitored after chemotherapy. Total leukocyte levels and peripheral blood eosinophilias were higher in these patients than in similar individuals with chronic schistosomiasis mansoni. In contrast to chronic patients, the eosinophilias of the acute cases were decreased rather than elevated upon treatment. Total lymphocyte population (T and B cell) percentages were not altered during acute infection. Lymphoid subset (T3+, T4+, and T8+) analysis revealed elevated levels of both T4+ and T8+ cells. In vitro blastogenic responses of peripheral blood mononuclear cells (PBMN) to heterogeneous schistosome-derived antigens (eggs, SEA; adult worms, AW; and cercariae, CERC) were evaluated. SEA responsiveness was considerably higher than that of patients with chronic S. mansoni infections. The ratios of SEA to AW responses in acute cases gave a mean of 2.0, as opposed to 0.5 for a comparable group of chronically infected patients. The sera of most acute patients already contained suppressive factors that specifically decreased schistosomal antigen-induced PBMN blastogenesis. Chemotherapy of acute cases lead to a diminution of PBMN responsiveness to SEA and CERC. Treatment of patients with chronic infections lead to the elevation of such responses. PBMN from patients with acute infections produced lymphokine leukocyte inhibition factor upon exposure of the cells to SEA but not AW. A similar pattern was true for production of the lymphokine activity mitogenic factor. Levels of antibody in sera of acutely infected patients against SEA, CERC, and AW were considerably higher than levels in sera of chronically infected patients matched for age and intensity of their infections. These high antibody titers persisted for at least 6 mo after treatment, and were unrelated to the intensity of infection. The immunologic status of these patients with acute schistosomiasis mansoni differed considerably from patients with chronic infections. These findings re-emphasize the immunoregulatory events that apparently develop upon continued exposure to schistosomes and their products during chronic infection.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4020142

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  16 in total

1.  Immune responses during human Schistosomiasis mansoni. Evidence for antiidiotypic T lymphocyte responsiveness.

Authors:  M S Lima; G Gazzinelli; E Nascimento; J C Parra; M A Montesano; D G Colley
Journal:  J Clin Invest       Date:  1986-10       Impact factor: 14.808

2.  Effect of praziquantel on certain immune responses of schistosomal Egyptian patients. II. Cell-mediated lymphoproliferative response.

Authors:  A E el-Bassiouny; Z A Shaker; A H el-Kalouby; E H el-Raziky
Journal:  Parasitol Res       Date:  1987       Impact factor: 2.289

3.  Similar cellular responses after treatment with either praziquantel or oxamniquine in Schistosoma mansoni infection.

Authors:  Takafira Mduluza; Francisca Mutapi; Tinashe Ruwona; Daniel Kaluka; Nicholas Midzi; Patricia D Ndhlovu
Journal:  Malawi Med J       Date:  2009-12       Impact factor: 0.875

Review 4.  Immunopathology of Schistosoma mansoni infection.

Authors:  D L Boros
Journal:  Clin Microbiol Rev       Date:  1989-07       Impact factor: 26.132

5.  Changes in the level of IL-2, T cell subsets and the function of T suppressor cells in patients with schistosomiasis japonica.

Authors:  Z J Li; J Z Dai; Y X Yang; L L Zeng; S L Li; Q Yang; H C Wang; D D Luo; X H Wang
Journal:  J Tongji Med Univ       Date:  1991

6.  Influence of exposure history on the immunology and development of resistance to human Schistosomiasis mansoni.

Authors:  Carla L Black; Pauline N M Mwinzi; Erick M O Muok; Bernard Abudho; Colin M Fitzsimmons; David W Dunne; Diana M S Karanja; W Evan Secor; Daniel G Colley
Journal:  PLoS Negl Trop Dis       Date:  2010-03-23

7.  Cross-reactivity of Schistosoma mansoni cytosolic superoxide dismutase, a protective vaccine candidate, with host superoxide dismutase and identification of parasite-specific B epitopes.

Authors:  Claudia Carvalho-Queiroz; Rosemary Cook; Ching C Wang; Rodrigo Correa-Oliveira; Nicola A Bailey; Nejat K Egilmez; Edith Mathiowitz; Philip T LoVerde
Journal:  Infect Immun       Date:  2004-05       Impact factor: 3.441

8.  T-cell abnormality and defective interleukin-2 production in patients with carcinoma of the urinary bladder with schistosomiasis.

Authors:  S Raziuddin; S Shetty; A Ibrahim
Journal:  J Clin Immunol       Date:  1991-03       Impact factor: 8.317

9.  Two distinct pathological syndromes in male CBA/J inbred mice with chronic Schistosoma mansoni infections.

Authors:  G S Henderson; N A Nix; M A Montesano; D Gold; G L Freeman; T L McCurley; D G Colley
Journal:  Am J Pathol       Date:  1993-03       Impact factor: 4.307

10.  Immunosuppressive effect of paracoccidioidomycosis sera on the proliferative response of normal mononuclear cells. Identification of a Paracoccidioides brasiliensis 34-kDa polypeptide in circulating immune complexes.

Authors:  D Chequer-Bou-Habib; M de F Ferreira-da-Cruz; B Galvão-Castro
Journal:  Mycopathologia       Date:  1992-08       Impact factor: 2.574

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.